Program
Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015
Its studies are mostly in Carcinoma, Ovarian Epithelial, led by Medigene.
Furthest: phase 1, since Dec 12, 20241 company-led study, 1 open or runningNext primary completion: Dec 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Medigene | 11 open or running | phase 1since Dec 12, 2024 | Dec 12, 2024 | Dec 1, 2027phase 1 · NCT06748872 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2024First study: phase 1 study in Carcinoma, Ovarian EpithelialFirst studyNCT06748872 · 55 planned · United States
Ahead
- Dec 1, 2027Primary completion: phase 1 study in Carcinoma, Ovarian EpithelialNCT06748872
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), and a progra”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06748872Carcinoma, Ovarian Epithelial · United States | 1 | Not yet recruiting | Dec 1, 2027 | 55 |
How it is read
Names in the registry
- “TCR-T cells (MDG1015)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.